2-azido-2,3-dihydro-1H-inden-1-ol | 1008361-84-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚满类
• 英文名称: 2-azido-2,3-dihydro-1H-inden-1-ol
• 英文别名: (+/-)cis-2-azido-2,3-dihydro-1H-inden-1-ol
• CAS: 1008361-84-9
• 化学式: C₉H₉N₃O
• 分子量: 175.19
• InChiKey: GXARJZSMOVQDPH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  34.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-azido-2,3-dihydro-1H-inden-1-ol 在 正丁基锂 、 lithium aluminium deuteride 作用下， 以 四氢呋喃 为溶剂， 反应 0.75h， 生成 (1S,2S)-2-amino-1-d-indane
  参考文献：
  名称：

  Enantioselective Synthesis of cis- and trans-2(S)-Amino-1-d-indane:  Debrominative [1,2]-Hydride Shift Rearrangement by Reduction of cis-2-Azido-1-bromoindane with LiAlD₄

  摘要：

  This article describes the synthesis of the racemic and optically pure forms of (1R,2S)-cis- and (1S,2S)-trans-2-Amino-1-d-indanes 2 {94% ee} and 3 {83% ee} (ee determined by H-2 NMR in chiral liquid crystal PBLG/CH2Cl2, Courtieu, J. et al. J. Am. Chem. Soc. 1995, 117, 6520) prepared by LiAlD4 reduction of (+/-)- and (1S,2S)-trans-2-azido-1-bromomoindane (11) {87% ee} and (+/-) and (1R,2S)-cis-2-azido-1-[(methanesulfonyl)oxy]indane (10) {83% ee}, respectively. Whereas the LiAlD4 reduction of trans-2-azido-1-bromomoindane (11) led to cis-2-amino-1-d-indane 2 by a S(N)2 pathway, exclusively, the reduction of cis-1-bromo derivative 12 gave only small amounts of the S(N)2 product trans-2-amino-1-d-indane (3) (15%) accompanied by 2-amino-2-d-indane (4) (85%) in which the deuterium atom is incorporated in alpha position to the amino group. It was established that the primary amine 4 comes from a stereospecific [1,2]-hydride shift rearrangement, We propose that the azido group is reduced first, and the [1,2]-hydride shift rearrangement prevails over the competitive S(N)2 substitution. The exclusive formation of trans-2-amino-1-d-indane (3) requires cis-2-azido-1-[(methanesulfonyl)oxy]indane (10) where the mesylate assisted by electrophilic Li+ cation switches the deuteride attack to the ester carbon and the direct S(N)2 substitution occurs before the azide is reduced.

  DOI：

  10.1021/jo970378o
• 作为产物：
  描述：

  茚 在 甲醇 、 sodium azide 、 manganese(II) bromide tetrahydrate 、 氧气 作用下， 以66 %的产率得到2-azido-2,3-dihydro-1H-inden-1-ol
  参考文献：
  名称：

  光化学锰介导的叠氮化物自由基生成以改善烯烃羟基叠氮化反应

  摘要：

  最先进的烯烃羟基叠氮化策略，产生β-叠氮醇和β-叠氮过氧化物的混合物，必须依靠膦试剂来提高化学选择性。为了克服上述问题，我们提出了一种通过 O 2中锰介导的配体到金属电荷转移 (LMCT) 进行烯烃的光化学羟基叠氮反应，将 N 3 –活化为•N 3并结合 O 2用作氧来源为羟基叠氮化产物。还证明了羟基叠氮化转化的广泛烯烃范围和步骤经济化学。

  DOI：

  10.1021/acs.orglett.4c00911

文献信息

• [EN] INDANE DERIVATIVES AS MGLUR7 MODULATORS<br/>[FR] DÉRIVÉS D'INDANE UTILISÉS COMME MODULATEURS DE MGLUR7
  申请人：TAKEDA PHARMACEUTICALS CO

  公开号：WO2017131221A1

  公开（公告）日：2017-08-03

  The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4a and R4b are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy. The compounds of formula (I) are mGluR7 modulators.

  本发明提供了式（I）的化合物及其药学上可接受的盐，其中R1、R2、R3、R4a和R4b如规范中定义，其制备方法，含有它们的药物组合物以及它们在治疗中的用途。式（I）的化合物是mGluR7调节剂。
• Mn-Catalyzed Highly Efficient Aerobic Oxidative Hydroxyazidation of Olefins: A Direct Approach to β-Azido Alcohols
  作者：Xiang Sun、Xinyao Li、Song Song、Yuchao Zhu、Yu-Feng Liang、Ning Jiao

  DOI：10.1021/jacs.5b02347

  日期：2015.5.13

  a novel approach to high value-added β-azido alcohols, which are useful precursors of aziridines, β-amino alcohols, and other important N- and O-containing heterocyclic compounds. This chemistry also provides an unexpected approach to azido substituted cyclic peroxy alcohol esters. A DFT calculation indicates that Mn catalyst plays key dual roles as an efficient catalyst for the generation of azido

  已开发出一种用于合成 β-叠氮醇的高效锰催化的烯烃有氧氧化羟基叠氮化反应。公开了以空气为末端氧化剂的叠氮自由基的有氧氧化生成是该转化的关键过程。该反应以其广泛的底物范围、廉价的锰催化剂、高效率、在空气中容易操作以及室温下温和的条件而受到赞赏。这种化学反应为高附加值的 β-叠氮醇提供了一种新方法，它是氮丙啶、β-氨基醇和其他重要的含 N 和 O 杂环化合物的有用前体。这种化学反应还为叠氮取代的环状过氧醇酯提供了一种意想不到的方法。DFT 计算表明，Mn 催化剂作为产生叠氮自由基的有效催化剂和过氧自由基中间体的稳定剂起着关键的双重作用。进一步的计算合理地解释了所提出的控制 CC 键断裂或形成 β-叠氮醇的机制。
• NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS
  申请人：Diaz Caroline Jean

  公开号：US20100222345A1

  公开（公告）日：2010-09-02

  This invention relates to novel compounds which are antagonists or inverse agonists at one or more of the opioid receptors, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy.

  这项发明涉及新型化合物，它们是阿片受体的拮抗剂或逆向激动剂之一，以及含有它们的药物组合物，它们的制备过程，以及它们在治疗中的应用。
• [EN] INDANE DERIVATIVES USEFUL AS MODULATORS OF MGLUR7<br/>[FR] DÉRIVÉS D'INDANE UTILES EN TANT QUE MODULATEURS DE MGLUR7
  申请人：TAKEDA PHARMACEUTICALS CO

  公开号：WO2018047983A1

  公开（公告）日：2018-03-15

  The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein n, X, Y, Z, D, R1, R2, R3, R4, R12, R15nd R16 are as defined in the specification, a process for their preparation, pharmaceutical compositions containing them and their use as modulators of mGluR7.

  本发明提供了化合物的公式(I)及其药用盐，其中n、X、Y、Z、D、R1、R2、R3、R4、R12、R15和R16如规范中所定义，以及它们的制备方法、含有它们的药物组合物以及它们作为mGluR7调节剂的用途。
• CYCLIC DIARYL ETHER COMPOUNDS AS ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS
  申请人：Hutchinson John Howard

  公开号：US20110098302A1

  公开（公告）日：2011-04-28

  Described herein are compounds that are antagonists of PGD 2 receptors. Also described are pharmaceutical compositions and medicaments that include the antagonists of PGD 2 receptors described herein, as well as methods of using such antagonists of PGD 2 receptors, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other PGD 2 -dependent or PGD 2 -mediated conditions or diseases.

  本文描述了PGD2受体拮抗剂化合物。还描述了包括本文所述的PGD2受体拮抗剂在内的制药组合物和药物，以及使用这种PGD2受体拮抗剂，单独或与其他化合物结合，治疗呼吸系统、心血管系统和其他PGD2依赖性或PGD2介导的疾病或病症的方法。